The complaint filed against Capricor Therapeutics, traded on the NASDAQ under the ticker CAPR, centers on claims that the company violated the Securities Exchange Act of 1934. Specifically, plaintiffs allege that while Capricor publicly touted the drug’s momentum toward FDA approval, leadership suppressed adverse findings from the Phase 2 HOPE-2 study. These omissions allegedly rendered the company’s market statements materially false.

Shareholders seeking to participate in the litigation may contact the DJS Law Group to discuss lead plaintiff status. While the deadline for initial filings passed on September 15, 2025, affected investors can still register to join the recovery efforts. The firm has stated that enrollment includes access to portfolio monitoring tools, noting that participation entails no direct cost or obligation for individual shareholders.